Most people researching ibogaine safety end up reading clinic websites, and clinic websites are written to reassure. Some of what they say is accurate. Some is accurate but incomplete, and a few claims are not supported by anything published. This article takes eight of the most common claims and sets each against what is actually known, so you can tell the difference before you pay a deposit or book a flight.
Why ibogaine safety claims need a second look
Ibogaine is a potent alkaloid with real effects on the heart, and the central fact is this: people have died during and after ibogaine treatment, in clinics as well as outside them. Heart rhythm problems are the suspected cause in many of those deaths. No one knows how often they happen, because there is no registry that every provider reports to and no rule that any of them must.
That gap is why the claims below deserve scrutiny. When a provider cannot be checked against public data, the only thing you can evaluate is whether what they tell you matches the published science and basic medical logic. The ibogaine safety protocols page covers the screening and monitoring steps in detail. This article is about the distance between those steps and the way they are sometimes sold.
One way to use the list: read each claim, then look for it in the exact wording on the website of any clinic you are considering. Marketing language repeats across the industry, and the same phrases turn up again and again.
Claims about the heart
Claim 1: screening and monitoring take care of the heart risk
What is known: ibogaine and its main metabolite, noribogaine, block a potassium channel in heart muscle cells called hERG, which lengthens the QT interval on an ECG. A review by Koenig and Hilber in the journal Molecules (2015) described this mechanism and the case reports of arrhythmia and death connected to it. A long QT interval sets the stage for a dangerous rhythm called torsades de pointes, which can stop the heart from pumping effectively.
Screening with an ECG and blood work identifies some people who should not be treated at all, such as those who already have a long QT or a structural heart problem. Continuous monitoring lets staff watch the interval change in real time. Monitored hospital patients have reached dangerous QT intervals. Monitoring can catch a dangerous rhythm early enough to treat it; it does not prevent one and can miss one. A clinic that presents screening and monitoring as the end of the conversation is overselling what those tools do, and a clinic that cannot tell you what QT measurement would make them stop has not thought it through.
Claim 2: magnesium covers the heart risk
What is known: magnesium is a reasonable precaution, not proven protection. No study has shown it prevents arrhythmia. Part of the idea comes from the Stanford MISTIC study published in Nature Medicine (2024), which gave magnesium alongside ibogaine to 30 special operations veterans under hospital monitoring. That was a small study without a comparison group, so it cannot show what magnesium did or did not do, and its findings on trauma and brain injury symptoms carry the same limitation.
The useful question is narrower. Ask whether potassium and magnesium are checked and corrected before dosing, and again after vomiting. Low levels of either make a long QT interval more dangerous, vomiting during treatment is common, and a clinic that gives magnesium without measuring it is following a ritual, not a protocol.
Claim 3: the fatalities belong to a different kind of provider
What is known: deaths have been reported in clinics and in unsupervised settings alike. Monitored patients have developed dangerous QT prolongation, and published fatality reports include settings where medical staff were present. The honest version of this claim is that a well-equipped clinic has staff and equipment on hand to respond. The dishonest version is that the risk lives somewhere else, and you can leave it behind by choosing the right address.
Claims about medications and other drugs
Claim 4: a slip after treatment is less dangerous than before
What is known: the opposite can be true. After treatment, opioid tolerance falls, by an amount no one can predict, so a dose used before can be a fatal overdose. Opioids may also act more strongly than expected in the weeks afterward, which compounds the problem. Anyone treated for opioid dependence should leave with naloxone, the people around them should know how to use it, and if someone stops responding, call emergency services immediately instead of waiting to see.
A clinic that talks about the treatment as the finish line, with nothing about naloxone or the first weeks at home, is leaving out the part of ibogaine safety that matters most once you are home.
Claim 5: a negative fentanyl test strip means the supply is fine
What is known: a negative fentanyl test strip does not make a drug safe. Strips can miss some analogues, they test only the portion of the drug you dissolved, and they say nothing about potency. Just as important for anyone reading outcome figures, no published ibogaine study has enrolled a fentanyl-using population. A clinic that quotes outcome data to someone using fentanyl is quoting data from a different group of patients, and should say so. Fentanyl also lingers in the body after heavy use, which complicates timing before treatment, and that timing is a conversation for the treating physician, not a website.
Claim 6: stop your antidepressant a few days before
What is known: ibogaine is cleared by a liver enzyme that varies from person to person, and some antidepressants block that enzyme. When it is blocked, ibogaine levels rise and stay higher for longer, which means a longer QT interval too. Those medications need weeks to wash out, not days. Stopping an antidepressant has its own risks and is done only with the prescriber who prescribed it; no intake form and no article should tell you to stop one.
The same part of a careful intake asks about alcohol and benzodiazepines. Heavy use of either must be stabilised under medical care first, because withdrawal seizures appear in the fatality reports. A clinic that accepts you a week after you last drank heavily, without a plan for that, is skipping a step.
Claims about the clinic itself
Claim 7: the clinic is licensed, so the treatment is approved
What is known: Mexico has not scheduled ibogaine, so it is unregulated there, not approved. A clinic can hold a health establishment license, which covers the facility as a medical premises, and that is not an approval of ibogaine. In the United States ibogaine is Schedule I, so no US facility can offer it outside a research setting. When a website blends these facts into a single word like "licensed" or "approved," ask exactly which document they mean, who issued it, and what it covers. The answer is usually a facility permit, which is worth having and is not what the word implied.
Claim 8: a perfect safety record
What is known: a clinic's own claim of no deaths cannot be checked. There is no outside body that audits ibogaine providers and no public registry of adverse events, so the statement rests entirely on the clinic's word. Unverifiable is a different thing from reassuring. A more useful question is what happened the last time a patient's QT interval crossed their threshold, and what they did about it. A clinic that has treated many people and has never needed to act on a monitor reading is either very lucky or not watching closely.
What to ask instead of taking the claim at face value
A claim is a starting point. These questions turn it into something you can evaluate, and the way a clinic answers them tells you as much as the content.
- Who reads my ECG, and what QT interval would stop the treatment? A clinic should have a number and a physician who applies it.
- Are potassium and magnesium checked before dosing and again after vomiting? Measured, not assumed.
- How is the heart monitored, for how long, and who is watching the monitor overnight? The QT interval commonly stays long past the first day, and in reported cases for more than a week.
- What is the emergency plan, and how far is the nearest hospital with a cardiac unit? Minutes, not "close by."
- When can I travel home? The right answer is after a normal ECG, not after a set number of days.
- Who will help me walk? You will need help walking for at least a day after a full dose.
- What do I do if I feel faint or my heart races in the first week? Fainting, a racing or irregular heartbeat, or a seizure is an emergency at any time, and the risk lasts at least the first week and until an ECG is normal.
- Can I take anti-nausea medicine or anything new afterward? Until an ECG is normal, no new medicine is started, anti-nausea drugs included, without asking a prescriber who knows about the ibogaine whether it affects the QT interval.
If you are still forming a picture of how the drug works, start with what is ibogaine, then move through the full ibogaine guide for the treatment process, costs and aftercare in sequence.
Ibogaine safety is less about finding a provider who says the right things and more about finding one who can show you how they do them. The ibogaine treatment guide covers screening, the treatment itself and the weeks after it in the order you will meet them. Read it before you book, and bring the answers you collect to a physician who knows your history.
Related Articles
Ibogaine Safety Timeline: Before, During and After
Ibogaine safety is not one decision on dosing day but a sequence of risks that peak at different times, from screening through the first week at home.
SafetyIbogaine Therapy Discharge: What to Settle First
Before ibogaine therapy ends, settle the ECG, the ride home, naloxone, medicines and follow-up, because the heart risk outlasts the clinic stay.
SafetyIbogaine for Fentanyl Addiction: Your Doctor's Role
Ibogaine for fentanyl addiction involves your own doctor before and after treatment: what to share, what to ask, and what no prescriber at home can do.